Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SPTLC2 | O15270 | 6/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148999 | 1.00 | HSD11B1 (0.52) | HSD11B1SLC6A3SPTLC2TAS1R3TAS1R1 | |
| SCHEMBL4153629 | 0.93 | SPTLC2 (0.44) | HSD11B1SLC6A3SPTLC2TAS1R3TAS1R1 | |
| SCHEMBL4153631 | 0.93 | SPTLC2 (0.44) | HSD11B1SLC6A3SPTLC2TAS1R3TAS1R1 | |
| SCHEMBL4149587 | 0.90 | TAS1R3 (0.52) | HSD11B1SPTLC2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4149585 | 0.90 | TAS1R3 (0.52) | HSD11B1SPTLC2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13814608 | 0.88 | HSD11B1 (0.48) | HSD11B1SLC6A3SPTLC2TAS1R3TAS1R1 | |
| SCHEMBL13801630 | 0.88 | HSD11B1 (0.48) | HSD11B1SLC6A3SPTLC2TAS1R3TAS1R1 | |
| SCHEMBL4148291 | 0.88 | TAS1R3 (0.51) | SPTLC2TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL4148294 | 0.88 | TAS1R3 (0.51) | SPTLC2TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL4157133 | 0.85 | SSTR3 (0.49) | HSD11B1SPTLC2TAS1R3TAS1R2SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HSD11B1 1023/4885SLC6A3 324/4885SPTLC2 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.